First chemotherapy for metastatic aggressive neuroendocrine cancer
Treatments studied
Part of Cancer clinical trials.
This Phase 2 study tests a chemotherapy approach in people with metastatic grade 3 (high-grade) neuroendocrine cancer or a related rare mixed tumor. It may help shrink tumors and control disease when standard first treatments have not yet been given.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your tumor must be grade 3 and poorly differentiated (or a mixed tumor where at least 30% is this grade 3 poorly differentiated part)
- Your cancer must be metastatic (spread to other body areas) and you must be starting treatment for metastatic disease for the first time
- You must have at least one tumor spot that can be measured on a CT scan or MRI
- Your key blood counts and liver/bile tests must be high enough (and bilirubin/AST/ALT must be within allowed limits)
- Your body strength and daily functioning must be fairly good (ECOG 0 to 1)
- You must not have had certain past chemo drugs, and you must not have conditions like major kidney problems, DPD deficiency, or active pregnancy/breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted therapies (surufatinib and serplulimab) plus standard chemotherapy (platinum and etoposide) for people with a rare, aggressive type of cancer called neuroendocrine carcinoma that started outside the lung. The goal is to see if this new combination works better than chemotherapy alone.
This study tests a new investigational drug called ZG006 against the chemotherapy your doctor would normally choose for advanced neuroendocrine carcinoma. The trial aims to see if ZG006 works better than standard chemotherapy for people whose cancer has progressed after earlier treatment.
This trial tests a drug called belinostat, possibly combined with other drugs, based on your genetic makeup. It aims to find the right dose for people with a rare and aggressive neuroendocrine cancer that started outside the lungs.
This trial tests a new combination of two immunotherapy drugs (zimberelimab and domvanalimab) added to a standard chemotherapy regimen called FOLFIRI, to see if it works better than FOLFIRI alone for a rare and aggressive type of cancer called neuroendocrine carcinoma. It is for people whose cancer has progressed after a first-line chemotherapy, and aims to help slow the cancer's growth.
This trial tests a new drug, LBL-024, combined with standard chemotherapy (etoposide and platinum) for people with advanced neuroendocrine carcinoma. The goal is to see if this combination works better than chemo alone.
This trial tests a chemotherapy drug called irinotecan liposomes for people with high-grade neuroendocrine tumors or neuroendocrine cancers of the digestive system. The goal is to see if this treatment can help shrink or control the tumors.
Hear when a new Neuroendocrine Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.